OR WAIT null SECS
October 23, 2024
Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance of properly characterizing HCPs in the biomanufacturing process.
October 21, 2024
Bala Addepalli, PhD, Director, R&D New Modalities Portfolio, Waters Corporation, discussed trends in new analytical tools for RNA characterization and gave highlights of his talk at AAPS PharmSci 360.
October 20, 2024
Bala Addepalli, PhD, Director, R&D New Modalities Portfolio, Waters Corporation, discussed recent advancements and current challenges in the development of large RNA therapeutics.
October 16, 2024
Collecting and curating R&D data are increasingly crucial tasks for achieving the full benefits of advanced analytics.
September 06, 2024
Viral vectors and other complex biologic modalities require more specificity and higher sensitivity to detect and distinguish contaminants.
August 06, 2024
Manual and automated inspection technologies have their own advantages and limitations.
July 13, 2024
Thermo Fisher will add Olink to its Life Sciences Solutions business.
July 05, 2024
Although advancements in analytical drug substance testing are being made, the increasing diversity of the therapeutic landscape is necessitating further innovation.
July 04, 2024
HCPs are major process-related impurities that must be monitored throughout biologics production for clearance.
June 11, 2024
A statistical analysis for determining an expiration date can be applied to replicates or their corresponding averages as suggested in industry guidelines.